Our global headquarters are in London and we employ around 98,000 people in 150 countries.
GSK India is headquartered at Worli, Mumbai with the manufacturing unit being located at Nashik. At present we are commissioning a second plant at Vemgal, Karnataka and the project is near completion. We have a clinical development centre in Bangalore. GSK's best-in-class field force, backed by a nation-wide network of stockists, ensures that the Company's products are readily available across the nation.
Our Nashik facility, inaugurated in 1983, is dedicated to the manufacture of Tablets, Capsules, Liquid Orals, Creams & Ointment and Injectables. It is situated on 47 acres of land in Ambad industrial belt, and has a committed workforce of 700 plus. Operational excellence is embedded into the site’s culture and is an integral part of its operating model.
The Nashik site has made significant progress in terms of building capability through implementing GPS, and recruitment of professionals, specifically in Quality, EHS and Manufacturing. The site endures its sustainability through energy conservation and environment friendly processes to manufacture high quality affordable products. The Company is upgrading the Nashik site by investing in infrastructure across all areas with special focus on Good Manufacturing Practices (GMP), Safety and Sustainability.
Bangalore facility (Vemgal):
To meet the growing demand for quality medicines in India, GSK is investing up to INR 1,000 (£100m) crores in a new ‘state of the art’ pharmaceutical factory in Bangalore. The new site will be the first Greenfield pharmaceutical site GSK has built across the globe in the last ten years. This site will also be the first factory designed for the new ‘GSK Production Systems’, whereby it will deliver by first design intent the concepts of zero accidents, defects and waste. The factory will be built with the future in mind and therefore, will be able to expand as required and incorporate other dose forms when necessary The factory will initially supply a range of solid dose form products and supply the Indian market, with first batches scheduled by the end of 2016. When completed, the factory will produce more than 9 billion tablets and capsules per year.
R&D set-up at Bangalore
- Clinical development operations centre, Bangalore (CDOC – B)
CDOC-B houses more than 100 staff working in Data Handling, Study Set Up, Scientific and Public Disclosure, Biometrics, Quality Risk Management and Clinical Project Management.
- Quantitative sciences India (QSI)
QSI provides Stats and SAS programming support to clinical and epidemiology studies within GSK R&D.
Our presence in India